References:
1. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345(20):1435-43.
2. Topkara VK, Kondareddy S, Malik F, et al. Infectious complications in patients with left ventricular assist device: etiology and outcomes in the continuous-flow era. Ann Thorac Surg. 2010;90(4):1270-7.
3. Kettner J, Holek M. HEART FAILURE 2013 POSTER SESSION: CLINICAL (poster no. 672). Wiley Online Library 2014. Available at:http://doi.wiley.com/10.1093/eurjhf/hst009. (abstract)
4. Oz MC, Gelijns AC, Miller L, et al. Left ventricular assist devices as permanent heart failure therapy: the price of progress. Ann Surg. 2003;238(4):577-83.
5. Laffey JG, Boylan JF, Cheng DC. The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. Anesthesiology. 2002;97(1):215-52.
6. Simon L, Gauvin F, Amre DK, Saint-louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39(2):206-17.
7. Jebali MA, Hausfater P, Abbes Z, Aouni Z, Riou B, Ferjani M. Assessment of the accuracy of procalcitonin to diagnose postoperative infection after cardiac surgery. Anesthesiology. 2007;107(2):232-8.
8. Prat C, Ricart P, Ruyra X, et al. Serum concentrations of procalcitonin after cardiac surgery. J Card Surg. 2008;23(6):627-32.
9. Samy Kallel, Mohamed Abid, Anouar Jarraya, Mohamed Abdenadher, Emna Mnif, Imed Frikha, Fatma Ayadi, Abdelhamid Karoui. Cinétique et intérêt diagnostique et pronostique de la procalcitonine après chirurgie cardiaque. Annales de Biologie Clinique. 2012;70(5):567-580. doi:10.1684/abc.2012.0745
10. Popov DA, Ovseenko ST, Vostrikova TY. [Procalcitonin as a predictor of bacteremia in postoperative cardiosurgery patients]. Anesteziol Reanimatol. 2014;(2):4-9.
11. Dong Z, Jianxin Z, Haraguchi G, Arai H, Mitaka C. [Procalcitonin for the differential diagnosis of infectious and non-infectious systemic inflammatory response syndrome after cardiac operation]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2014;26(7):478-9.
12. Kettner J, Holek M, Franekova J, et al. Procalcitonin dynamics after long-term ventricular assist device implantation. Heart, Lung and Circulation, 2017; 26(4): 599-603.
13. Wu J, Hu L, Zhang G et al.: Accuracy of Presepsin in Sepsis Diagnosis: A Systematic Review and Meta-Analysis. PLOS ONE 2015; 10(7), e0133057
14. Bellomo R, Ronco C, Kellum J A et al.: Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical care 2004; 8, R204
15. Anand D, Das S, Ray S, Bhargava S, Srivastava LM. Interrelationship between procalcitonin and organ failure in sepsis. Indian J Clin Biochem. 2014;29(1):93-6.
16. Villanueva MP, Mollar A, Palau P, et al. Procalcitonin and long-term prognosis after an admission for acute heart failure. Eur J Intern Med. 2015;26(1):42-8.
17. Loncar G, Tscholl V, Tahirovic E, et al. Should procalcitonin be measured routinely in acute decompensated heart failure?. Biomark Med. 2015;9(7):651-9.
18. Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. The role of complement in biomaterial-induced inflammation. Mol Immunol. 2007;44(1-3):82-94.
19. Nagata T, Yasuda Y, Ando M et al.: Clinical Impact of Kidney Function on Presepsin Levels. PLOS ONE 2015; 10(6), e0129159